C. Patterson

发表

Ibrutinib in previously treated Waldenström's macroglobulinemia.

R. Advani, N. Harris, J. Aster, 2015, The New England journal of medicine.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.

Karan P. Singh, S. Greenland, S. Treon, 2012, Cancer epidemiology.

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

K. Anderson, N. Munshi, S. Treon, 2009, Clinical Cancer Research.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

N. Munshi, S. Treon, Z. Hunter, 2008, Blood.

Macroglobulinemia CD27-CD70 interactions in the pathogenesis of Waldenstrom's

N. Munshi, Z. Hunter, E. Hatjiharissi, 2008 .

Novel agents in the treatment of Waldenström's macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2007, Clinical lymphoma & myeloma.

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

S. Treon, Z. Hunter, A. Branagan, 2021, Haematologica.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

S. Treon, Z. Hunter, R. Ojha, 2011, Clinical lymphoma, myeloma & leukemia.

Report from the Sixth International Workshop on Waldenström's Macroglobulinemia.

S. Treon, G. Merlini, E. Morra, 2011, Clinical lymphoma, myeloma & leukemia.

IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia

S. Treon, Z. Hunter, M. Morra, 2010, Haematologica.

Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.

E. Kimby, S. Treon, M. Stone, 2009, Clinical lymphoma & myeloma.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

R. Advani, S. Treon, Z. Hunter, 2017, Blood.

Resveratrol Exerts AntiproliferativeActivity and Induces Apoptosis inWaldenstro« m’s Macroglobulinemia

F. Dammacco, S. Treon, A. Roccaro, 2008 .

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

N. Munshi, M. Samur, S. Treon, 2018, Blood advances.

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib

M. Kersten, T. Ganz, S. Treon, 2017, Haematologica.

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

E. Kimby, N. Munshi, R. Kyle, 2013, British journal of haematology.

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

S. Treon, N. Raje, Z. Hunter, 2021, Leukemia.

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

S. Treon, Z. Hunter, J. Castillo, 2020, HemaSphere.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas

N. Munshi, N. Gray, Jinhua Wang, 2022, Blood advances.

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

S. Treon, A. Roccaro, A. Sacco, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2009, Clinical lymphoma & myeloma.

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

J. Kutok, Jiangwen Zhang, N. Munshi, 2007, Experimental hematology.

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

S. Verselis, E. Fox, S. Treon, 2009, British journal of haematology.

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

D. Skifter, S. Lincoln, J. Laramie, 2011 .

A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

N. Harris, G. Pinkus, S. Rodig, 2011 .

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

S. Treon, Z. Hunter, L. Ioakimidis, 2011, Blood.

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012, Clinical lymphoma, myeloma & leukemia.

The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

S. Treon, A. Roccaro, A. Sacco, 2008, British journal of haematology.

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2017, British journal of haematology.

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells

N. Munshi, Hsiuyi Tseng, S. Treon, 2011, Leukemia & lymphoma.

Cell‐free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia

T. P. White, S. Treon, Z. Hunter, 2021, American journal of hematology.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

S. Treon, A. Roccaro, A. Sacco, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

S. Treon, Z. Hunter, L. Ioakimidis, 2011, British journal of haematology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naı̈ve patients with Waldenstrom Macroglobulinaemia who respond

S. Treon, Z. Hunter, L. Ioakimidis, 2011 .

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

N. Harris, D. Skifter, S. Lincoln, 2012, The New England journal of medicine.

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

S. Treon, Z. Hunter, Guang Yang, 2014, Blood.

small somatic deletions associated with B-cell lymphomagenesis characterized by highly recurring MYD 88 and WHIM-like CXCR 4 mutations , The genomic landscape of Waldenstöm ' s Macroglobulinemia

S. Treon, Z. Hunter, Guang Yang, 2013 .

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

S. Treon, Z. Hunter, J. Castillo, 2020, American journal of hematology.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2019, Blood advances.

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2014, Blood.

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

S. Rodig, S. Treon, J. Chen, 2014, Leukemia.

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin M monoclonal gammopathy , and other B-cell lymphoproliferative disorders using conventional and quantitative allele-speci fi c polymerase chain reaction

N. Munshi, N. Lindeman, S. Treon, 2013 .

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

M. Kersten, E. Kimby, M. Dimopoulos, 2017, Haematologica.

Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.

N. Lindeman, S. Treon, C. Tripsas, 2013, Clinical lymphoma, myeloma & leukemia.

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy, and other B-cell lymphoproliferative MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M

N. Munshi, N. Lindeman, S. Treon, 2013 .

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy , and other B-cell lymphoproliferative MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin

N. Munshi, N. Lindeman, S. Treon, 2013 .

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

S. Treon, P. Gokhale, Z. Hunter, 2021, Blood.

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

S. Treon, Z. Hunter, J. Castillo, 2016 .

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

R. Advani, J. Laubach, S. Treon, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

R. Advani, E. Kimby, M. Dimopoulos, 2016, Blood.

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

R. Advani, S. Treon, I. Ghobrial, 2011 .

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

S. Treon, L. Ioakimidis, R. Manning, 2011, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

S. Treon, Z. Hunter, L. Ioakimidis, 2010 .

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

N. Munshi, N. Gray, Jinhua Wang, 2021, Blood.

Epigenomics in Waldenstrom's macroglobulinaemia.

S. Treon, A. Roccaro, A. Sacco, 2016, Best practice & research. Clinical haematology.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

N. Gray, Jinhua Wang, S. Treon, 2018, Blood.

BTK drives ibrutinib resistance via ERK1/2, and protects BTK MYD88 mutated cells by a paracrine mechanism

Amanda, N. Gray, Jinhua Wang, 2018 .

Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia

F. Dammacco, S. Treon, A. Roccaro, 2008, Clinical Cancer Research.

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Rodig, S. Treon, 2011, Clinical lymphoma, myeloma & leukemia.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions

S. Treon, A. Roccaro, A. Sacco, 2017, Oncotarget.

Venetoclax in Previously Treated Waldenström Macroglobulinemia

R. Advani, M. Davids, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

S. Treon, Z. Hunter, A. Branagan, 2021, Blood advances.

Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, A. Branagan, 2021, British journal of haematology.

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2020, Leukemia & lymphoma.

Comparative genomics of CXCR4 MUT and CXCR4 WT single cells in Waldenstr¨om ’ s macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2020 .

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2019, American journal of hematology.

MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4

M. Cazzola, S. Treon, Z. Hunter, 2018, Haematologica.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

S. Treon, I. Ghobrial, Z. Hunter, 2016, Clinical Cancer Research.

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

N. Lindeman, S. Treon, Z. Hunter, 2013 .

Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2021, Blood.

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

N. Gray, S. Treon, Y. Tai, 2013, Blood.

Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy

M. Hansen, S. Verselis, E. Fox, 2007 .

Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Hsiuyi Tseng, S. Verselis, E. Fox, 2011, British journal of haematology.

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

S. Treon, N. Raje, Z. Hunter, 2017 .

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

N. Lindeman, S. Treon, J. Chen, 2014, Leukemia.

macroglobulinemia neuropathy-sparing approach for treating Waldenström's Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a

I. Ghobrial, J. Castillo, Guang Yang, 2014 .

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2013 .

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

M. Pasmantier, S. Treon, Z. Hunter, 2004, Blood.

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.

D. Dorfman, S. Treon, Z. Hunter, 2005, Clinical lymphoma.

Characterization of familial Waldenstrom's macroglobulinemia.

C. Lee, C. Morton, S. Treon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.

N. Munshi, S. Treon, M. Fulciniti, 2011, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

R. Advani, J. Laubach, S. Treon, 2017 .

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Wei Zhang, P. Cohen, Shuai Liu, 2016, Blood.

Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2007 .

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues

S. Treon, A. Roccaro, I. Ghobrial, 2007 .

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

S. Treon, I. Ghobrial, Z. Hunter, 2006 .

Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079.

S. Treon, Z. Hunter, B. Kahl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2021, HemaSphere.

IBRUTINIB MONOTHERAPY PRODUCES LONG‐TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821).

J. Laubach, I. Ghobrial, Z. Hunter, 2019, Hematological Oncology.

Somatic Activating Mutations In CXCR4 Are Common In Patients With Waldenstrom’s Macroglobulinemia, and Their Expression In WM Cells Promotes Resistance To Ibrutinib

S. Treon, Z. Hunter, Guang Yang, 2013 .

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

R. Advani, J. Laubach, S. Treon, 2013 .

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2022, Blood.

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Treon, E. Hatjiharissi, 2009, Clinical lymphoma & myeloma.

Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.

R. Advani, S. Treon, Z. Hunter, 2005 .

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2015 .

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2018, Blood.

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.

Hsiuyi Tseng, S. Treon, Jingrui Jiang, 2011, Clinical lymphoma, myeloma & leukemia.

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

S. Treon, L. Ioakimidis, C. Patterson, 2008 .

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance

S. Treon, Z. Hunter, B. Ciccarelli, 2010 .

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

N. Gray, S. Treon, Z. Hunter, 2017, British journal of haematology.

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

P. Cohen, N. Gray, S. Treon, 2015 .

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2007, American journal of hematology.

Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom’s macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012 .

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

N. Gray, Jinhua Wang, S. Treon, 2020, Blood Cancer Journal.

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.

J. Kutok, S. Treon, Y. Tai, 2006, Clinical lymphoma & myeloma.

Thalidomide in Combination with Rituximab Is Active in Waldenström’s Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

S. Treon, Z. Hunter, A. Branagan, 2005 .

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

S. Treon, Z. Hunter, A. Branagan, 2005 .

MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase

S. Treon, Y. Tai, Z. Hunter, 2012 .

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.

M. Hansen, S. Verselis, E. Fox, 2007, Clinical lymphoma & myeloma.

Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia.

S. Treon, Z. Hunter, Guang Yang, 2012 .

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.

S. Treon, Z. Hunter, B. Ciccarelli, 2013, Clinical lymphoma, myeloma & leukemia.

Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia.

F. Dammacco, S. Treon, A. Roccaro, 2007 .

Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM).

S. Treon, Z. Hunter, X. Leleu, 2006 .

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

N. Munshi, S. Treon, Z. Hunter, 2006 .

Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile

S. Treon, Jingrui Jiang, Z. Hunter, 2010 .

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM).

S. Verselis, E. Fox, S. Treon, 2006 .

Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia.

S. Treon, Z. Hunter, X. Leleu, 2005 .

Characterization of familial Waldenstrom's Macroglobulinemia.

C. Morton, S. Treon, Z. Hunter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plenary Paper

S. Treon, Z. Hunter, Guang Yang, 2014 .

Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors.

S. Treon, Y. Tai, Z. Hunter, 2012 .

Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care.

S. Treon, C. Patterson, R. G. Sanz, 2023, Seminars in hematology.

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

N. Gray, S. Treon, Z. Hunter, 2015 .

Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling.

C. Mitsiades, S. Treon, A. Roccaro, 2007 .

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

R. Advani, N. Harris, J. Aster, 2015, The New England journal of medicine.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

N. Gray, S. Treon, Z. Hunter, 2017, British journal of haematology.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

BTKCys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

S. Treon, Z. Hunter, J. Castillo, 2017 .

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

R. Advani, S. Treon, Z. Hunter, 2016 .